ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...

Sipuleucel-T A therapeutic cancer ... melanoma (ipilimumab) are in Phase III testing in mCRPC and may provide additional immunotherapy options. Emerging Therapies in Prostate Cancer The ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

BMS has bucked the trend for late-stage immuno-oncology studies in prostate cancer in the CheckMate 650 trial Opdivo in combination with CTLA4 inhibitor Yervoy (ipilimumab), which showed modest ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Darolutamide also demonstrated benefits across secondary endpoints, including time to castration-resistant prostate cancer and PSA progression ... evaluating nivolumab 3mg/kg and ipilimumab 1mg/kg in ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...